Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination (Q39695552)

14 September 2017

Efficacy of RAD001 (everolimus) against advanced gastric cancer with peritoneal dissemination (English)

1 reference

14 September 2017

Fumiko Taguchi

1

1 reference

14 September 2017

Yasuo Kodera

2

1 reference

14 September 2017

Yasufumi Katanasaka

3

1 reference

14 September 2017

Kazuyoshi Yanagihara

4

1 reference

14 September 2017

Tomohide Tamura

5

1 reference

14 September 2017

Fumiaki Koizumi

6

1 reference

14 September 2017

8 June 2010

1 reference

Investigational New Drugs

14 September 2017

1 reference

14 September 2017

29

1 reference

14 September 2017

6

1 reference

14 September 2017

1198-1205

1 reference

https://scigraph.springernature.com/pub.10.1007/s10637-010-9464-9

14 September 2017

0 references

cites work

Randomized phase III trial of fluorouracil alone versus fluorouracil plus cisplatin versus uracil and tegafur plus mitomycin in patients with unresectable, advanced gastric cancer: The Japan Clinical Oncology Group Study (JCOG9205).

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

Effective therapy for peritoneal dissemination in gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

The role of mTOR in the management of solid tumors: an overview

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

Mammalian target of rapamycin is activated in human gastric cancer and serves as a target for therapy in an experimental model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

Insulin stimulates hypoxia-inducible factor 1 through a phosphatidylinositol 3-kinase/target of rapamycin-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

The mTOR inhibitor RAD001 sensitizes tumor cells to DNA-damaged induced apoptosis through inhibition of p21 translation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

RAD001 inhibits human ovarian cancer cell proliferation, enhances cisplatin-induced apoptosis, and prolongs survival in an ovarian cancer model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

Hypoxia in head and neck cancer: how much, how important?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

Establishment of two cell lines from human gastric scirrhous carcinoma that possess the potential to metastasize spontaneously in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

A photon counting technique for quantitatively evaluating progression of peritoneal tumor dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

RAD001 (everolimus) improves the efficacy of replicating adenoviruses that target colon cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

Hepatocyte growth factor (HGF) produced by peritoneal fibroblasts may affect mesothelial cell morphology and promote peritoneal dissemination

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

VEGF receptor antisense therapy inhibits angiogenesis and peritoneal dissemination of human gastric cancer in nude mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

Blocking on the CXCR4/mTOR signalling pathway induces the anti-metastatic properties and autophagic cell death in peritoneal disseminated gastric cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

Selective killing of hypoxia-inducible factor-1-active cells improves survival in a mouse model of invasive and metastatic pancreatic cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

A novel hypoxia-inducible factor-independent hypoxic response regulating mammalian target of rapamycin and its targets.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

Suppression of PI3K/mTOR pathway rescues LLC cells from cell death induced by hypoxia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS10637-010-9464-9

Adjuvant therapy for gastric carcinoma patients in the past 15 years: a review of western and oriental trials

21 January 2018

1 reference

12 December 2020

V-SRC induces expression of hypoxia-inducible factor 1 (HIF-1) and transcription of genes encoding vascular endothelial growth factor and enolase 1: involvement of HIF-1 in tumor progression.

1 reference

12 December 2020

Pathology and prognosis of gastric carcinoma. Findings in 10,000 patients who underwent primary gastrectomy

1 reference

12 December 2020

1 reference

12 December 2020

Final results of a randomized phase III trial of sequential high-dose methotrexate, fluorouracil, and doxorubicin versus etoposide, leucovorin, and fluorouracil versus infusional fluorouracil and cisplatin in advanced gastric cancer: A trial of the

1 reference

12 December 2020

Up-regulation of hypoxia-inducible factor-1 alpha and VEGF mRNAs in peritoneal dissemination of patients with gastric cancer.

1 reference

12 December 2020

The surgical treatment of cancer of the stomach

1 reference

12 December 2020

Development and biological analysis of peritoneal metastasis mouse models for human scirrhous stomach cancer

1 reference

12 December 2020

Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial

1 reference

12 December 2020

Prognostic significance of serosal invasion in carcinoma of the stomach

1 reference

12 December 2020

Adenocarcinoma of the stomach: areas of failure in a re-operation series (second or symptomatic look) clinicopathologic correlation and implications for adjuvant therapy

1 reference

12 December 2020

High CD40 expression in gastric cancer associated with expanding type histology and liver metastasis

1 reference

12 December 2020

Clinical significance of epidermal growth factor (EGF) expression in gastric cancer

1 reference

12 December 2020

10.1007/S10637-010-9464-9

Identifiers

DOI

1 reference

14 September 2017

1 reference